Article ; Online: Morbidity associated with the use of oxaliplatin versus mitomycin C in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal or appendiceal origin: a multi-institutional comparative study.
Canadian journal of surgery. Journal canadien de chirurgie
2021 Volume 64, Issue 2, Page(s) E111–E118
Abstract: Background: The raw costs of mitomycin C (MMC) and oxaliplatin for hyperthermic intraperitoneal chemotherapy (HIPEC) differ substantially. We sought to compare the morbidity and toxicity profiles associated with the use of oxaliplatin and MMC in ... ...
| Abstract | Background: The raw costs of mitomycin C (MMC) and oxaliplatin for hyperthermic intraperitoneal chemotherapy (HIPEC) differ substantially. We sought to compare the morbidity and toxicity profiles associated with the use of oxaliplatin and MMC in patients undergoing cytoreductive surgery (CRS) and HIPEC for peritoneal carcinomatosis (PC) of colorectal or appendiceal origin, to evaluate whether the costeffectiveness of these 2 agents should dictate drug choice. Methods: We conducted a retrospective multi-institutional study of all patients with PC of colorectal or appendiceal origin treated with CRS-HIPEC using MMC or oxaliplatin from 2010 to 2015. Demographic, perioperative, morbidity, toxicity and cost data were compared between the 2 treatment groups and between cancer-origin subgroups. Results: Forty-two patients treated with MMC and 76 treated with oxaliplatin were included in the study. Baseline demographic and tumour characteristics were comparable in the 2 groups, except that the patients treated with MMC had higher Charlson Comorbidity Index scores. The MMC group had a higher rate of cancer of colorectal origin (76.2% v. 57.9%, p = 0.047) and longer operative times (553 v. 320 min, p < 0.001). In the subgroup of patients whose cancer was of colorectal origin, patients treated with MMC had a higher transfusion rate (50.0% v. 28.6%, p = 0.023) and lower postoperative baseline hemoglobin level (100 v. 119 g/L, p = 0.002) than those treated with oxaliplatin. There was no difference in hematologic toxicity scores after controlling for postoperative anemia. There was no difference in the rates of major complications and 90-day mortality. However, MMC was less costly than oxaliplatin ($724 v. $8928). Conclusion: MMC and oxaliplatin are both suitable agents for HIPEC and are associated with comparable morbidity and toxicity profiles, regardless of cancer origin. Thus, we propose that cost-effectiveness should ultimately dictate drug selection. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Adult ; Aged ; Antineoplastic Agents/adverse effects ; Appendiceal Neoplasms/drug therapy ; Colorectal Neoplasms/drug therapy ; Female ; Humans ; Hyperthermic Intraperitoneal Chemotherapy ; Male ; Middle Aged ; Mitomycin/adverse effects ; Morbidity ; Oxaliplatin/adverse effects ; Peritoneal Neoplasms/drug therapy ; Retrospective Studies | |||||
| Chemical Substances | Antineoplastic Agents ; Oxaliplatin (04ZR38536J) ; Mitomycin (50SG953SK6) | |||||
| Language | English | |||||
| Publishing date | 2021-03-02 | |||||
| Publishing country | Canada | |||||
| Document type | Comparative Study ; Journal Article ; Multicenter Study | |||||
| ZDB-ID | 410651-9 | |||||
| ISSN | 1488-2310 ; 0008-428X | |||||
| ISSN (online) | 1488-2310 | |||||
| ISSN | 0008-428X | |||||
| DOI | 10.1503/cjs.001619 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 221: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.